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ABSTRACT
Objective: Idiopathic thrombocytopenic purpura (ITP) is an immuunological disorder characterized by the production of antibodies targeted toward 
platelets. Corticosteroids and intravenous immunoglobulins were the mainstay of immediate treatment after 1950s with splenectomy for more than 
100 years remains the only option with curative potential. The aim of this study was to analyze the incidence, age and sex distribution among adults, 
various modes of presentation, correlation between thrombocytopenia and bleeding manifestations, and various modalities of treatment of ITP in a 
tertiary care hospital in India..
Methods: A prospective study included 40 cases of ITP admitted to Kasturba Medical College Hospital, Manipal, from November 2005 to March 
2007. Patients above 14 years of age admitted with thrombocytopenia in this institution were screened based on detailed clinical history, physical 
examination, and laboratory investigations.
Results: The maximum incidence was in the 3rd decade of life accounting for 27.5% of the patients. Male-to–female ratio was 1:1.9 with female 
preponderance. Females in the 3rd decade had maximum incidence while males in the 4th decade have maximum incidence. The majority (12, 85.71%) 
of male patients and 15 (57.69%) female patients developed purpura during the course of disease. The mean count was 17.8×109/L with range 
between 2.0×109/L and 76×109/L. Cutaneous bleeding spots were found to be associated with counts above 25000×109/L and hematuria with lowest 
counts around 4000×109/L. A number of 20 (50%) of the above 40 patients responded to corticosteroids alone and did not have any further relapse. 
Among the remaining patients, 3 (7.5%) had a relapse of symptoms within next 6 months and responded to repeat prednisolone started at 1 mg/kg. 
2 (5%) patients were given steroids tapering dose with IV immune globulins for initial 5 days as therapy to which they responded.
Conclusion: Idiopathic thrombocytopenia is 1.9 times more common in females than males. Most common presentation is bleeding spots over body. 
Bleeding manifestations are more common with thrombocytopenia <30000/mm3. Corticosteroids are the mainstay in treatment. Complete remission 
is seen in up to 57.5% of the patients. Splenectomy is the second modality of treatment in ITP. Complete and sustained remission is seen 75% of 
patients.
Keywords: Idiopathic thrombocytopenic purpura, Splenectomy, Steroids, Purpura.
INTRODUCTION
Platelets are one of the three formed elements other than red and white 
blood cells which are seen in blood. These cells play an important role 
as far as hemostasis in the body is concerned. Platelets are susceptible 
to various forms of injury such as drugs, toxins, and viruses other than 
antibodies which destroy them by autoimmune mechanism [1,2]. Thus, 
idiopathic thrombocytopenic purpura (ITP) can be considered as an 
immunological disorder that has received lot of attention in recent years. 
In 1735, a German physician Paul Gottlieb Werlhof described ITP nearly 
10 decades before Victor Hugo’s published his novel Les misérables. 
ITP has an incidence of 6/100000, and the licensing of thrombopoietin 
mimetic agents has added a good paradigm to its management [3,4]. 
Corticosteroids and intravenous immunoglobulins were the mainstay 
of immediate treatment after 1950’s with splenectomy for more than 
100 years remains the only option with curative potential. The center 
point in pathogenesis of this disorder is the production of antibodies 
targeted toward platelets as a result of derangement in immunological 
machinery of body wherein body fails to recognize these miniature cells 
as self. These antibodies get attached to platelets, which are destroyed 
and filtered off by the spleen. This results in decrease in number of 
platelets in peripheral blood giving rise to platelet manifestations [5].
There have been few numbers of studies carried out on ITP, but only a 
very few are in Indian subcontinent. This study was undertaken on ITP 
to study the incidence, age and sex distribution among adult, various 
modes of presentation, correlation between thrombocytopenia and 
bleeding manifestations, and various modalities of treatment instituted 
in this hospital.
METHODS
A prospective study consists of 40 cases of ITP admitted to Kasturba 
Medical College Hospital, Manipal, from November 2005 to March 
2007.  Ethical approval was taken from the institutional ethical board. 
Patients above 14 years of age admitted with thrombocytopenia 
in this institution were screened based on detailed clinical history, 
physical examination, and laboratory investigations. All patients were 
inpatients, in whom detailed workup was done in hospital.
Inclusion criteria*1
1. Platelet count <1,00,000/mm3
2. Megakaryocyte hyperplasia on bone marrow examination
3. Positive antiplatelet antibody test.
∗	 Peripheral	 blood	 examination,	 bone	 marrow	 examination,	
antiplatelet antibody test, platelet factor 3 assay, antinuclear 
antibody,	and	human	 immunodeficiency	virus	by	enzyme-linked	
immunosorbent assay were done to all patients.
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Exclusion criteria*2
1. History of recent ingestion of drugs known to cause thrombocytopenia
2. Clinical or laboratory evidence of microangiopathy or disseminated 
intravascular coagulation
3. Clinical evidence of chronic liver disease with portal hypertension 
or any evidence of hypersplenism
4.	 The	presence	of	clinical	evidence	sufficient	to	diagnose	connective	
tissue diseases such as rheumatoid arthritis or systemic lupus 
erythematosus at presentation.
RESULTS
Forty patients of more than 14 years old admitted during the study 
were analyzed for age distribution. Patients varied from the second 
to 8th decades with the youngest patient being 15 years old and oldest 
being 75 years old. The maximum incidence was in the 3rd decade of life 
accounting for 27.5% of the patients (Table 1 and Fig. 1).
Of the total 40 patients, 14 were male and 26 were female. Male: female 
ratio was 1:1.9 with female preponderance (Table 2 and Fig. 2). Females 
in the 3rd decade had maximum incidence while males in the 4th decade 
have maximum incidence (Table 3 and Fig. 3). Among male patients, 
cutaneous bleeding spots including petechiae, purpura, and ecchymosis 
were the most common presenting symptoms. There was no predilection 
for any part of the body. The other presenting symptoms were bleeding 
gums, epistaxis, malena, and hematuria (Table 4 and Fig. 4).
Cutaneous bleeding spots (10, 38.46%) were the most common initial 
presenting symptom in females also. Menorrhagia (26.72%) was the 
initial presenting symptom in a significant percentage of patients in 
our study. Other less common presentations in females were bleeding 
gums, epistaxis, malena, hematuria, and hemoptysis (Table 5 and 
Fig. 5). The majority (12, 85.71%) of male patients and 15 (57.69%) 
female patients developed purpura during the course of disease. Other 
common manifestations were gum bleeding in males (28.57%) and 
females (34.61%), easy bruisability in females (11.53%) and males 
(21.42%), epistaxis in females (15.38%), malena in females (11.53%), 
and hematuria in males (14.28%). Menorrhagia (42.30%) was the 
second most common presentation in females (Table 6 and Fig. 6). 
One male and female patient had mild splenomegaly with tip of spleen 
palpable 2 cm below the left costal margin without any clinical or 
investigational features (anti-nuclear antibody negative) to suggest a 
secondary cause for thrombocytopenia.
The mean count was 17.8×109/L with range between 2.0×109/L and 
76×109/L. It was seen that 19 patients (42%) had platelets between 
10 and 30×109/L with 14 patients having platelet count <10×109/L 
(Table 7). Correlation between the platelet count and clinical features of 
the patient at time of presentation (Table 8) was found and cutaneous 
bleeding spots were found to be associated with counts above 
25000×109/L and hematuria with lowest counts around 4000×109/L.
All patients were started on prednisolone at 1 ml/kg as initial therapy. 
Of 40 patients, 20 (50%) responded to corticosteroids alone and did not 
have any further relapse. The corticosteroids were tapered over a period 
of 4-6 weeks and stopped. Among the remaining patients, 3 (7.5%) had 
a relapse of symptoms within next 6 months and responded to repeat 
prednisolone started at 1 mg/kg and tapered over 6 weeks. These 
patients responded completely and did not have any further symptoms. 
Another 4 (10%) patients who relapsed were started on dapsone along 
with steroids as therapy of which 1 (2.5%) patient was also started on 
danazol, all patients responded to therapy over a period of 6-8 weeks 
without further relapse. 2 (5%) patients were given steroids tapering 
dose with IV immune globulins for initial 5 days as therapy to which 
they responded (Table 9).
* Peripheral blood examination, bone marrow examination, 
antiplatelet antibody test, platelet factor 3 assay, antinuclear 
antibody,	and	human	 immunodeficiency	virus	by	enzyme-linked	
immunosorbent assay were done to all patients
Among the remaining 13 (32.5%) patients who did not have an 
adequate response or patients who relapsed to initial medical 
therapy with steroids alone or along with immunosuppressive 
treatment, 8 (20%) had splenectomy done to which 6 had adequate 
response and complete remission. One of the two patients who did 
not have a response is steroid dependent on low-dose prednisolone, 
having recurrence of symptoms on stopping steroids. The another 
patient with inadequate response to splenectomy is on therapy 
Table 1: Distribution of cases according to age











Table 3: Distribution of cases according to sex and age of 
patients
Age (years) Number of patients Males Females
14-20 7 4 3
21-30 11 1 10
31-40 9 5 4
41-50 6 4 2
51-60 4 1 3
>60 3 1 2
Fig. 1: Distribution of cases as per age
Fig. 2: Sex-wise distribution of idiopathic thrombocytopenic 
purpura
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with danazol. Among the remaining 5 (12.5%) patients, 3 (7.5%) 
are steroid dependent on low-dose maintenance steroids with oral 
prednisolone. One patient is on dapsone therapy, another patient 
was initially started on dapsone, but it was discontinued due to 
development of methemoglobinemia and is on treatment with 
azathioprine.
DISCUSSION
ITP refers to thrombocytopenia in which apparent exogenous factors 
are lacking and in which diseases known to be associated with 
Fig. 3: Distribution of cases as per sex and age
Fig. 4: Presenting symptoms males
Fig. 5: Presenting symptoms females
Fig. 6: Common manifestations of idiopathic thrombocytopenic 
purpura in males and females
Table 4: Presenting symptoms of male patients
Symptom presentation Number of patients male (%)
Cutaneous bleeding spots 8 (57.14)




Table 5: Symptoms female patients
Symptoms Number of patients (%)
Cutaneous bleeding spots 10 (38.46)
Menorrhagia 7 (26.92)





Table 6: Common manifestations of ITP in male sand females
Clinical features Males (%) Females (%)
Purpura 12 (85.17) 15 (57.69)
Menorrhagia - 11 (42.30)
Gum bleeding 4 (28.57) 9 (34.61)
Epistaxis - 4 (15.38)
Easy bruisability 3 (21.42) 3 (11.53)
Malena - 3 (11.53)
Hematuria 2 (14.28) -
ITP: Idiopathic thrombocytopenic purpura
Table 7: Platelet count in idiopathic thrombocytopenia





Table 8: Platelet count and clinical features at presentation
Clinical features Mean platelet count/mm3







Table 9: Modalities of treatment instituted







IV Ig: Intravenous immune globulin
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secondary thrombocytopenia have been excluded. Females are affected 
3-4 times more than males, and a seasonal fluctuation is noted with 
peak in spring and early summer and a nadir in winter. Acute ITP 
usually occurs in children <6 months and chronic ITP affects the adults. 
Pathophysiology of ITP includes inhibition of thrombopoiesis, platelet 
phagocytosis, antiplatelet antibody formation, antibody-mediated 
platelet destruction, and direct T-cell-mediated cytotoxicity against 
platelets in chronic ITP [5-15]. Clinically ITP presents as acute and 
chronic.
Acute ITP is usually sudden with history of infections preceding the 
bleeding by 2-3 weeks in 84% of cases [16]. Bleeding manifestations 
are usually mild [17] and intracranial hemorrhage in <1% of patients. 
It is usually self-limited with spontaneous remissions in 90% of 
cases [16]. Splenomegaly has been reported in 10% of patients [18]. 
The duration of disease ranges from few days to weeks with an average 
of 4-6 weeks [19].
Chronic ITP is insidious with long history of hemorrhagic symptoms 
of mild to moderate severity. Antecedent infections, fever, and 
splenic enlargement are uncommon with a fluctuating clinical course 
commonly seen. Spontaneous remissions are uncommon and are likely 
to be incomplete with cyclical or intermittent episodes of bleeding 
lasting few days to weeks. Relapses in some cases occur due to 
vaccination [20].
In this study, it was observed that ITP occurs over age group from 
2nd to 8th decades with maximum incidence in the 3rd followed by the 
4th decade. This observation is similar to that seen in other studies 
like those by Brown and Eliott [21], Portielje et al. [22], and Branehög 
et al. [23]. However, in a study conducted by Wong and Lee [24], the 
maximum incidence was in patients above 50 years followed by those 
in 4th decade. With respect to sex distribution, 65% of patients in this 
study were female with male: female ratio of 1:1.9, similar to incidence 
seen in studies conducted by Branehög et al. [23] and Wong and 
Lee [24].
The overall most common presenting symptom was bleeding spots 
over the body. Purpuric spots were distributed all over the body 
without predilection to any specific site. In studies conducted by Difino 
et al. [25], Portielje et al. [22], and Wong and Lee [24], the most common 
mode of presentation was purpuric spots on body. Among the male 
patients, the second most presentation was bleeding gums whereas 
among female patients it was menorrhagia. Wong and Lee [24] also 
reported menorrhagia as a common presenting complaint in females. 
Doan et al. [19] had reported one patient whose only symptom was 
menorrhagia. In this study, there were three patients whose only 
symptom was menorrhagia. Lacey and Penner [26] had reported 
a case with history on intracranial bleed with no history of bleeding 
manifestation before that. A similar case was reported by Wong and 
Lee [24]. However, in the present study, no patient presented with 
intracranial bleed.
Splenomegaly is rarely found in patients with ITP. However, spleen 
may be palpable in 5% of patients as described by Doan et al. [19]. In 
the current study, 2 patients had mild splenomegaly. An attempt was 
made to correlate between the platelet count and clinical feature at 
presentation. Mean platelet counts varied from 28856/mm3 in patients 
with purpura to 4000/mm3 in patients with hematuria. This was similar 
to study conducted by Wong and Lee [24]. However, patients presented 
with menorrhagia at a higher platelet count in that study (Table 10).
Complete remission to steroids was observed in 57.5% of the patients. 
Studies conducted by Portielje et al. [22] and Wong and Lee [24] 
revealed remission in 67.7% and 46.7% of patients, respectively. About 
75% of patients in the current study had sustained remission. Similar 
results were obtained in studies by Portielje et al. [22] with remission of 
75% and that conducted by Wong and Lee [24] with remission of 64.9%. 
Laros and Penner [27] and Caplan and Berkman [28] have reported 
44-55% response to azathioprine in patients with refractory ITP. In 
this study, three patients required maintenance immunosuppressive 
therapy.
CONCLUSION
Idiopathic thrombocytopenia is 1.9 times more common in females than 
males. Adults with ITP present between the second and 8th decade with 
maximum incidence in the 3rd and 4th decades of life. Patients present 
with various hemorrhagic manifestations. Most common presentation 
is bleeding spots over body. Subsequently, they may develop symptoms 
of bleeding at other sites such as menorrhagia, epistaxis, malena, and 
hematuria. Splenic enlargement is very common in ITP. However, spleen 
may be just palpable in 5% of patients with this disorder. Severity of 
bleeding manifestations corresponds to degree of thrombocytopenia. 
Bleeding manifestations are more common with thrombocytopenia 
<30000/mm3. Corticosteroids are the mainstay in treatment. Complete 
remission is seen in up to 57.5% of the patients. Splenectomy is the 
second modality of treatment in ITP. Complete and sustained remission 
is seen 75% of patients. Patients who do not have an adequate response 
can be treated with either immunosuppressive drugs or maintenance 
dose of corticosteroids.
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